Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 7 pages · Chinese
Hinova Pharmaceuticals, Inc. on 6ix
Earlier from Hinova Pharmaceuticals
- Announcement on Change of Sponsor Representative
- Announcement on Voluntary Disclosure of Completion of Inclusion of All Participants in Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on the Company's Successful GMP Compliance Inspection and the Amendment of Its Drug Manufacturing License
- Earnings Preannouncement for 2025
Later from Hinova Pharmaceuticals
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Reply to Inquiry Letter for Information Disclosure Supervision of 2025 Annual Report
- Voluntary Disclosure Announcement on Receipt of Notice of Approval for Initiation of a Phase III Clinical Trial of Deuterated Enzalutamide Soft Capsules for High-risk Biochemical Recurrence (BCR) Prostate Cancer
- Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors
- Announcement on Public Solicitation of Voting Rights by CHINA SECURITIES INVESTOR SERVICES CENTER CO., LTD.
Follow Hinova Pharmaceuticals into a list and get an email when it puts out news.
Follow Hinova Pharmaceuticals